PV Bulletin

Update to listed medicine ingredients in June 2026

The Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 has been updated, introducing changes to the requirements for several listed medicine ingredients.

Primary source: https://www.tga.gov.au/news/news-articles/update-listed-medicine-ingredients-june-2026

PV Impact Brief

Urgency: HighConfidence: high

What changed

The requirements for several listed medicine ingredients have been revised, necessitating compliance with new permissible ingredients and updated safety requirements.

Why it matters

These changes affect the formulation and safety compliance obligations for sponsors of listed medicines, impacting product availability and market adherence.

Action needed

Sponsors must align their products with the updated safety and formulation requirements for permissible ingredients as per the new determination.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Notice
Policy status
final
Publication date
2026-06-18
Policy change
The Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 has been updated, introducing changes to the requirements for several listed medicine ingredients, including additions of new substances and changes to existing entries.

Key changes

Addition of new permissible ingredients and update of safety requirements/restrictions for existing ingredients in the Therapeutic Goods Determination.

Affected workflows

Country Compliance

Responsible groups

Regulatory AffairsProduct Safety

PV impact

Sponsors of listed medicines must ensure that their products comply with the updated safety and formulation requirements for permissible ingredients.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 18, 2026

Full briefing

Practical implication

Sponsors must align their products with the updated safety and formulation requirements for permissible ingredients as per the new determination.

The TGA has updated the Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026, implementing new permissible ingredients and modifying safety requirements for existing ones. Sponsors of listed medicines must now ensure compliance with these updated safety and formulation standards.

What changed: The requirements for several listed medicine ingredients have been revised, necessitating compliance with new permissible ingredients and updated safety requirements.

Why it matters: These changes affect the formulation and safety compliance obligations for sponsors of listed medicines, impacting product availability and market adherence.

Practical implication: Sponsors must align their products with the updated safety and formulation requirements for permissible ingredients as per the new determination.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Notice#final#Therapeutic Goods Administration (TGA)#guidance#policy-change#firecrawl-policy-agent

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward